Poly-Dtech

Poly-Dtech — Reinventing Detection to Accelerate Research and Drug Discovery

Poly-Dtech is a French biotech developing patented ultra-fluorescent nanoparticles designed to transform how researchers and industry players detect biomarkers.

Our mission: to accelerate research and drug discovery by providing faster, more sensitive, and more affordabletesting solutions.

A Breakthrough Technology for Life Sciences

Current detection technologies — such as ELISA or traditional multiplex assays — face major limitations: they are slow, expensive, complex, and lack sensitivity.

Poly-Dtech changes this with its Bright-Dtech™ technology, a patented lanthanide-doped nanoparticle platformcombining ultra-sensitivity, ease of use, speed, and universal compatibility.

Concrete Solutions for the Market

TR-FRET (Time-Resolved Fluorescence Resonance Energy Transfer) is a “mix & read” method that allows highly precise biomolecular interaction detection without wash steps.

Poly-Dtech has mastered and simplified this powerful approach to make it accessible to any laboratory.

• NoW-Dtech™: single-target TR-FRET assays — ultra-sensitive, rapid (1–2 hours).
• Multi-Dtech™: world’s first TR-FRET multiplex assays — enabling simultaneous measurement of several biomarkers with single-test precision.

Multiplexing in TR-FRET, made possible by Bright-Dtech™, is unique worldwide and a game changer for the sector.

Key advantages:

✅ 3× faster results

✅ 3× lower costs than conventional methods

✅ Simplified protocols, no special equipment required

✅ Plug-and-play compatibility with existing lab instruments — zero additional investment

Poly-Dtech delivers a universal detection solution to address the challenges of researchers, pharma, and CROs, combining performance, flexibility, and cost efficiency.

A Market in Rapid Transformation

The global in vitro diagnostics (IVD) market (TAM 2024: $5.1B, 9.6% CAGR) is shifting toward next-generation fluorescent immunoassays.

This is a recurrent, high-growth market, driven by the increasing need for screening and drug discovery assays to identify tomorrow’s therapies.

Poly-Dtech is the first company democratizing TR-FRET multiplexing, delivering premium precision at an accessible cost.

Target customers include pharma and biotech companies, CROs, diagnostic kit manufacturers, and hospital labs.

An Experienced Team and a Clear Expansion Plan

Founded by Joan Goetz (CEO) and Dr. Loïc Charbonnière (CSO), Poly-Dtech relies on a leadership team combining over 20 years of experience in life science product commercialization, CNRS academic research, and deep-tech innovation.

The company is supported by a Tier-1 scientific board, including Prof. Niko Hildebrandt, a world-leading TR-FRET expert.

Fundraising and Growth Outlook

Poly-Dtech is currently raising €7.5M to:

• Accelerate R&D and expand its biomarker panel (up to 12 simultaneous targets by 2029);
• Scale production and achieve ISO certification;
• Invest over 50% of proceeds into marketing, sales, and strategic partnerships in drug discovery and diagnostics;
• Deploy internationally across Europe, Boston, and Hong Kong.

Our ambition: reach €12M in revenue by 2029, achieve profitability by 2028, and establish Poly-Dtech as the global reference in TR-FRET multiplexing.